NuVasive To Showcase Comprehensive Solutions For Complex Spinal Deformities At Scoliosis Research Society Annual Meeting
SAN DIEGO, Oct. 4, 2018 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will highlight several of its latest spinal innovations to treat complex spinal deformities at the Scoliosis Research Society (SRS) Annual Meeting held October 10-13, 2018 in Bologna, Italy. As a Double Diamond Sponsor of SRS, NuVasive continues to demonstrate a strong leadership position in offering transformative solutions within the complex adult and pediatric deformity market segments.
“The NuVasive deformity portfolio is one of the most differentiated portfolios in the market offering surgical efficiency, operative reliability and procedural versatility,” said Matt Link, executive vice president, strategy, technology and corporate development for NuVasive. “This latest expansion of the NuVasive deformity portfolio is a further testament of our commitment to building out comprehensive treatment options for both adult and pediatric patients.”
NuVasive’s complex spine technologies are recognized as best-in-class solutions. Since the introduction of the RELINE® posterior fixation portfolio in May 2015, the overall complex fixation business line, defined as cases with more than five levels of spinal correction, has experienced double-digit revenue growth. This validates NuVasive’s solutions are being utilized by more surgeons to help treat some of the most high-risk patients, and the Company continues to look for new opportunities to further invest in this growing market.
During the meeting, NuVasive will demonstrate several of its latest technologies for complex spinal deformities:
- VersaTie® is a posterior band system designed to provide clinical versatility and flexibility in the treatment of complex spinal pathologies in both adult and pediatric patients. The system provides primary and supplemental fixation options for patients where traditional fixation may not be feasible. VersaTie supports advanced spine translation techniques in adolescent idiopathic scoliosis (AIS) patients by providing controlled, hands-free translation, and will be commercially available at the end of October 2018. For adult deformity patients, VersaTie offers an advanced solution for distributed loading across the fixation hardware. The band system’s independent locking connector and advanced tensioning device offers enhanced control to address the variable needs of spine surgery. VersaTie’s adult application will be commercially available by end-of-year, and feature a unique new band providing increased strength characteristics.
- RELINE Navigation.S consists of new instrumentation that offers a complete navigation-compatible solution with surgical navigation. Optimal screw placement and pullout resistance are key surgical objectives to building a strong fixation construct in the adult deformity market, and this new system offers surgeons navigation-compatible instrumentation to optimize clinical outcomes during complex cases.
- RELINE Small Stature (RSS), launched in July 2018, is the first pediatric deformity fixation solution to accept 4.5mm, 4.75mm and 5.0mm rods in a low-profile tulip, combining rod strength with low-profile implants. With RSS, surgeons have the ideal implant profile for young children without compromising on rod strength within the system. The RSS system was built to give surgeons heightened anatomical awareness through the instrumentation, and provide final fusion strength with a 5.0mm Cobalt Chrome rod option for reliable deformity correction. RSS is also compatible with NuVasive’s MAGEC® system to provide a comprehensive solution for the treatment of Early Onset Scoliosis.
NuVasive will also showcase LessRay®, its hardware and software technology that helps reduce radiation exposure in the operating room (OR), which is particularly important when treating pediatric patients. In addition, the Company’s new Pulse™ surgical automation platform will be on display with the Siemens Healthineers’ Cios Spin* advanced mobile 3D-imaging system, creating the industry’s first Spine Precision Partnership™. These integrated systems can be clinically utilized throughout all deformity and degenerative spinal cases, and has the ability to enhance the OR procedural workflow and offer real-time feedback to aid in clinical decision making.
*Cios Spin from Siemens Healthineers is pending 510(k) clearance, and is not yet commercially available in the U.S.
About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company’s portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With over $1 billion in revenues, NuVasive has an approximate 2,400 person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.
Forward-Looking Statements
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA® platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
SOURCE NuVasive, Inc.
Related Links
